Plain-English translation of NCT06996080 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new medication called tabirafusp alfa () to see if it can reduce swelling in the back of the eye caused by inflammation. The medication is given as an injection directly into the eye. Researchers want to understand whether this treatment helps people see better and is safe to use.
Swelling in the macula (the part of the eye responsible for clear, detailed vision) caused by inflammation can damage vision and is difficult to treat with existing options. This trial is testing whether this new medication could offer patients a better way to reduce that swelling and protect their sight.
You likely qualify if…
You likely don't qualify if…
You would receive eye injections every 4 weeks for the first 6 months, then your dosing schedule would be adjusted based on how you respond. You'd be randomly assigned to receive either the new medication at one of two doses or a sham injection (a pretend injection with no medication). Throughout the trial, you would have regular eye exams and imaging scans to see how well the treatment is working and to monitor for any side effects.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States